Q-omics provides the consensus-scored SMTNL1 profile across patient tissues and cancer cell-line models. SMTNL1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SMTNL1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SMTNL1 RNA expression shows 18,222 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where SMTNL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMTNL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMTNL1 survival associations across molecular data types. SMTNL1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMTNL1 RNA expression–survival associations across cancer types. High SMTNL1 expression shows unfavorable associations in KIRP, KIRC and UCEC, but favorable associations in SKCM, UCS and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SMTNL1 RNA expression.
This table summarizes SMTNL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SMTNL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMTNL1 shows lower tumor expression in HNSC and higher tumor expression in KIRC, KICH, STAD, BLCA and COAD. The KIRC box plot shows higher SMTNL1 RNA expression in tumor versus normal tissue (log2 FC = +0.341, t-test p < 0.001).
This table shows molecular features associated with SMTNL1 in patient tissues and cancer cell lines. In patient samples, SMTNL1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMTNL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
